Bionime Corporation AI Stock Analysis
Bionime Corporation (4737) AI Stock Analysis
Bionime Corporation
(TWSE:4737)
The score is driven primarily by deteriorating financial performance: three consecutive years of operating losses, an 11-point gross margin decline since 2020, flat-to-falling revenue, and rising leverage (~1.75x debt-to-equity) against a shrinking equity base. Technicals reinforce the caution, with the price trading below all major moving averages and momentum indicators soft. Valuation offers no cushion — earnings are negative and there is no dividend. The main mitigating factor is a genuine improvement in cash generation, with operating cash flow at a multi-year high and free cash flow positive for the first time since 2020, but this needs to prove durable and translate into restored margins before the outlook improves.
Bionime Corporation (4737) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 4.34B
- Dividend Yield
- ―
- Average Volume (3M)
- 79.24K
- Price to Earnings (P/E)
- -13.6
- Beta (1Y)
- 0.22
- Revenue Growth
- -9.37%
- EPS Growth
- -132.26%
- Country
- TW
- Employees
- 1,111
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Instruments & Supplies
Bionime Corporation Business Overview & Revenue Model
Company Description
Bionime Corporation, headquartered in Taichung, Taiwan, specializes in the development, production, and global distribution of medical instruments. The company maintains a significant international presence, serving markets in countries such as China...
Bionime Corporation Financial Statement Overview
Summary
Bionime's fundamentals are weak. Revenue has stalled near NT$1.84bn (-3.9% in the latest year) and remains below the 2022 peak, while gross margin has compressed roughly 11 points since 2020 to about 34%. The company has posted operating losses for three straight years, with the net loss widening to NT$180m (-9.8% net margin). Leverage has risen sharply — debt of NT$3.06bn against shrinking equity of NT$1.75bn (~1.75x debt-to-equity) — and ROE is negative near -10%. The one clear positive is cash flow: operating cash flow hit a multi-year high of NT$495m and free cash flow turned positive at NT$206m for the first time since 2020, suggesting the heavy capex cycle is easing. Still, with losses driving the equity base lower, the overall picture is of a company in a defensive, transitional phase.
Income Statement
27NegativeBalance Sheet
36NegativeCash Flow
52Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.72B | 1.84B | 1.93B | 1.76B | 2.21B | 1.85B |
| Gross Profit | 561.22M | 627.81M | 768.38M | 715.65M | 1.00B | 783.13M |
| EBITDA | -152.56M | -15.08M | 59.28M | 179.78M | 270.36M | 248.29M |
| Net Income | -285.36M | -180.28M | -127.22M | 6.21M | 91.03M | 87.41M |
Balance Sheet | ||||||
| Total Assets | 5.65B | 5.70B | 5.78B | 5.30B | 4.98B | 4.56B |
| Cash, Cash Equivalents and Short-Term Investments | 444.78M | 485.01M | 382.59M | 449.21M | 277.88M | 312.91M |
| Total Debt | 2.66B | 3.06B | 3.17B | 2.82B | 2.27B | 2.03B |
| Total Liabilities | 3.54B | 3.95B | 3.89B | 3.31B | 2.90B | 2.49B |
| Stockholders Equity | 2.10B | 1.75B | 1.88B | 1.99B | 2.07B | 2.07B |
Cash Flow | ||||||
| Free Cash Flow | -53.49M | 206.41M | -313.29M | -237.95M | -170.63M | -14.85M |
| Operating Cash Flow | 125.88M | 494.80M | 19.53M | 203.44M | 142.29M | 269.72M |
| Investing Cash Flow | -194.31M | -286.07M | -336.90M | -435.26M | -312.26M | -288.07M |
| Financing Cash Flow | 76.57M | -108.53M | 217.30M | 420.40M | 113.64M | -69.30M |
Bionime Corporation Peers Comparison
Overall Rating
TW:176064Neutral- TW:473739Underperform
TW:472635Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TW:1760 | 64Neutral | TWD 4.23B | 24.71 | ― | 4.19% | 1.43% | -5.24% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:4737 | 39Underperform | TWD 4.18B | -13.55 | ― | ― | -9.37% | -132.26% |
| TW:4726 | 35Underperform | TWD 4.76B | -12.16 | ― | ― | 52.81% | 38.53% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:4737 | Bionime Corporation | 55.70 | -6.69 | -10.72% | |
| TW:1271 | SunWay Biotech Co., Ltd. | 58.80 | -3.76 | -6.01% | |
| TW:1760 | Panion & BF Biotech Inc. | 47.70 | -16.06 | -25.18% | |
| TW:4726 | Mycenax Biotech Inc. | 22.40 | -11.25 | -33.43% | |
| TW:6610 | TWi Biotechnology, Inc | 17.50 | -19.34 | -52.50% | |
| TW:6634 | Sinew Pharma, Inc. | 63.20 | 22.70 | 56.05% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026